-
Tislelizumab Earns European Approval in Non–Small Cell Lung Cancer
23 Apr 2024 17:43 GMT
… for patients with non–small cell lung cancer (NSCLC) in the … as treatment for non-small cell lung cancer. News release. BeiGene, … for advanced squamous non–small-cell lung cancer: a phase 3 … as treatment for non-small cell lung cancer. News release. BeiGene, …
-
Research Progress of Baihe Gujin Decoction in the Treatment of Lung Cancer
23 Apr 2024 17:30 GMT
… small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) are the two primary subtypes of lung cancer … Lung Cancers
Clinical Study of Baihe Gujin Decoction in the Treatment of Lung Cancer … Non-Small Cell Lung Cancer
… stage small-cell lung cancer: an …
-
Alecensa Approved as First and Only ALK Inhibitor for Non-Small Cell Lung Cancer
23 Apr 2024 11:44 GMT
… lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
The approval was based … with early-stage ALK-positive lung cancer, who until now, were not … people diagnosed with early-stage lung cancer undergo testing for ALK and …
-
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
23 Apr 2024 10:17 GMT
… a treatment for non-small cell lung cancer (NSCLC) across three … receiving tislelizumab.
“Non-small cell lung cancer remains one of the … related death worldwide.1 Lung cancer is the third … lung cancers.2 In 2020, the number of new cases of lung cancer …
-
Lung Cancer Cells Switch Oncogenic Drivers
23 Apr 2024 13:08 GMT
… from lung adenocarcinoma to small cell lung cancer in mice. Eric … cancer type known as small cell lung cancer (SCLC).
To gain deeper … Eric Gardner, a lung cancer biologist at Weill Cornell … given the heterogeneity of lung cancer.
Watanabe believes that there …
-
AFNT-211 by Affini-T Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
23 Apr 2024 03:29 GMT
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role …
-
Lantern Pharma cleared to expand lung cancer treatment trial
23 Apr 2024 11:50 GMT
… -300, for treating non-small cell lung cancer (NSCLC).
The multicentre, … and researcher of lung cancer at the National Cancer … significant therapeutic option for lung cancer patients in Japan … Taiwan, where many lung cancer diagnoses occur among never …
-
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
22 Apr 2024 12:34 GMT
… LP-300 in non-small cell lung cancer (NSCLC) in never … distinct from smoking-related lung cancers and occur almost … the incidence of non-small cell lung cancer (NSCLC) in never-smokers … never-smokers battling advanced lung cancer."
The Harmonic™ …
-
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
22 Apr 2024 12:10 GMT
… in MTAP-deletion squamous non-small cell lung cancer (NSCLC), based on adverse event … -in-mtap-deletion-squamous-non-small-cell-lung-cancer-302122601.html
SOURCE IDEAYA Biosciences …
-
Preoperative Physical Dysfunction Characteristics and Influence Factors Among Elderly Patients with Early Lung Cancer: A Latent Class Analysis
22 Apr 2024 17:30 GMT
… parameters in elderly lung cancer patients were associated … stage I-II non-small cell lung cancer: an evaluation of … for patients with lung cancer undergoing curative intent … postsurgically treated for non-small cell lung cancer: a systematic review and …